Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LBP-EC01,Trimethoprim,Sulfamethoxazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LBP-EC01 is a Locus crPhage® therapy in development for the treatment of urinary tract infections and other infections caused by the pathogen Escherichia coli (E. coli). It is a bacteriophage cocktail engineered with a CRISPR-Cas3 construct targeting th...
Brand Name : LBP-EC01
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 13, 2022
Lead Product(s) : LBP-EC01,Trimethoprim,Sulfamethoxazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sulfamethoxazole,Trimethoprim
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Premier
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under terms of this partnership, Somerset Pharma will supply sulfamethoxazole/trimethoprim, an antibiotic combination used to treat respiratory infections, a common complication associated with COVID-19, to Premier.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 04, 2020
Lead Product(s) : Sulfamethoxazole,Trimethoprim
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Premier
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?